Dr. Reddy's Laboratories Ltd Common Stock (RDY)
Stock · NYSE · Health Care
$13.07as of 10/16/2026
Price chart
Active signals
RDY Signal Track Record
How signals performed across all stocks →What RDY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 30 | +0.1% | 50% | July 9, 2026 |
| Volume Spike | 27 | +0.7% | 56% | September 2, 2026 |
| Bollinger Band Breakdown | 22 | +1.6% | 59% | September 8, 2026 |
| Bollinger Band BreakoutActive now | 21 | -0.3% | 43% | September 22, 2026 |
| Any 20-session window (baseline) | +0.3% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 27,527
- Website
- www.drreddys.com/
Fundamentals
- 1-day range
- $12.94$13.07
- Market cap
- $10.11B
- P/E (trailing)
- 31.61
- P/E (forward)
- 20.38
- EPS (trailing)
- $38.67
- Dividend yield
- 0.71%
- Beta
- 0.02
- Avg. volume
- 2.90M
- Ex-dividend date
- July 9, 2026
- Dividend pay date
- August 5, 2026
Forecasts
5 analyst ratings
Dr. Reddy's Laboratories Ltd Common Stock Competitors
Chosen by industry and closest market cap.
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavarambenzinga · 10/8/2026
- Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In PydibhimavaramBenzinga · 10/8/2026
- Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450Benzinga · 9/29/2026
- ONO, Gilead Announce Exclusive License Agreement to Develop ONO-4059 for Treatment of B-cell Malignancies and Other DiseasesBenzinga · 9/17/2026
- Dr Reddy's Laboratories Q1 2027 Earnings Call TranscriptBenzinga · 9/17/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 114.13M
- Total value held
- $1.52B
- Institutional holders
- 241
- Unknown17.18M
- Unknown11.59M
- Unknown9.98M
- Unknown9.37M
- Unknown8.00M
- Unknown7.86M
- Unknown5.32M
- Unknown4.03M
- Unknown3.18M
- Unknown3.10M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Dr. Reddy's Included in Oracle, Amex Stock Report
Dr. Reddy's Laboratories was mentioned in a recent market roundup alongside Oracle and American Express. The report highlights current stock trends but does not provide specific new financial data or strategic updates for the pharmaceutical company. This inclusion places the stock in a broader context of major corporate movements without altering its immediate fundamentals.
Dr. Reddy's Included in Oracle, Amex Stock Report. Dr. Reddy's Laboratories was mentioned in a recent market roundup alongside Oracle and American Express. The report highlights current stock trends but does not provide specific new financial data or strategic updates for the pharmaceutical company. This inclusion places the stock in a broader context of major corporate movements without altering its immediate fundamentals.